Tekmira Reports New Interim Clinical Data From TKM-PLK1 Oncology Phase 1 Clinical Trial Conference Call at 4:30 pm Eastern Time Today VANCOUVER, B.C., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its financial and operating results for the second quarter ended June 30, 2012 and provided a corporate update. "Over the past few months, significant clinical data have been reported providing further validation that Tekmira's LNP technology is the 'gold standard' and most widely-used delivery technology in the RNAi field. Building on this momentum, we are releasing interim TKM-PLK1 results demonstrating that TKM-PLK1 is showing promising signs of drug activity in an ongoing Phase 1 human clinical trial," said Dr. Mark J. Murray, Tekmira's President and CEO. "We believe Tekmira is entering the second half of the year in a solid position, bolstered by positive RNAi clinical data and the recent news that Talon was granted accelerated approval for Marqibo, which triggered a milestone payment to Tekmira. The Court's decision in July to deny Alnylam and AlCana's requests to file motions for summary judgment means that the ongoing litigation will proceed to trial on all counts this fall – and all issues will be decided by a jury," added Dr. Murray. TKM-PLK1 Phase 1 Clinical Data "We are very encouraged with the interim results from our ongoing Phase 1 human clinical trial for TKM-PLK1 in an advanced and heavily pre-treated population of cancer patients with solid tumors. TKM-PLK1 is being dosed on an aggressive once weekly protocol and the drug has been generally well tolerated. In addition, we have seen encouraging signs of drug activity with one patient achieving a 63% reduction in tumor burden (partial response) and who remains on study after receiving 15 doses of drug over 5 months, and another patient achieving stable disease who received 18 doses of TKM-PLK1 over 6 months," added Dr. Murray.